Exelixis announces European Commission approval of COTELLICTM (Cobimetinib)
Exelixis announced the EC has approved COTELLIC™ (cobimetinib) for use in combination with vemurafenib for treatment of adult patients with unresectable metastatic melanoma with a BRAF V600 mutation. COTELLIC, discovered by Exelixis, is the subject of a collaboration between Exelixis and Genentech. November 25, 2015